Physician profile
Iram Nawaz
NPI 1992967269
$7,114.96
in general payments reported to CMS, 2019-2025
43 companies · $2,373 in 2025
The $2,373 reported for 2025 was more than what 79% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,241 · 2020: $473 · 2021: $216 · 2022: $195 · 2023: $758 · 2024: $1,858 · 2025: $2,373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,957 · Education: $32.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,956.99 |
| Education | $32.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,163.13 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $877.95 | 2019-2025 | Ofev, Jascayd |
| Genzyme Corporation | $684.10 | 2020-2025 | |
| Astrazeneca Pharmaceuticals Lp | $623.91 | 2019-2025 | Airsupra, Breztri, Tagrisso |
| Insmed, INC. | $389.64 | 2020-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $232.32 | 2020-2025 | Prolastin-C Liquid |
| Mylan Specialty L.P. | $226.27 | 2019-2024 | Yupelri |
| Actelion Pharmaceuticals US, INC. | $223.39 | 2019-2025 | Opsumit, Uptravi |
| Takeda Pharmaceuticals U.S.A., INC. | $220.52 | 2020-2025 | Aralast, Glassia |
| Amgen INC. | $219.27 | 2023-2025 | Tezspire |
| Regeneron Healthcare Solutions, INC. | $202.94 | 2024-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $176.34 | 2019-2025 | Zerbaxa |
| Sunovion Pharmaceuticals INC. | $160.74 | 2019 | |
| Baxter Healthcare | $142.14 | 2024-2025 | Hillrom - Vest System Model 105 Home Care |
| Abbvie INC. | $115.42 | 2021-2024 |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $115.22 | 2022-2024 | Tyvaso, Orenitram, Remodulin |
| Inogen, INC. | $112.54 | 2022-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Pulmonx Corporation | $109.50 | 2019 | |
| Gilead Sciences, INC. | $103.93 | 2023-2024 | Veklury |
| Verona Pharma, INC. | $103.47 | 2025 | Ohtuvayre |
| Paratek Pharmaceuticals, INC. | $101.51 | 2023-2025 | Nuzyra |
| Mallinckrodt Hospital Products INC. | $65.89 | 2020-2024 | Acthar |
| Genentech USA, INC. | $64.59 | 2019 | |
| Ethicon INC. | $64.19 | 2024 | Monarch Platform |
| Shionogi INC | $58.48 | 2024 | Fetroja |
| Vifor Pharma, INC. | $51.93 | 2024 | Zemaira |
| Csl Behring | $51.20 | 2023-2025 | Kcentra |
| Shire North American Group INC | $50.99 | 2019 | |
| Electromed, INC. | $48.68 | 2023-2025 | Smartvest |
| Medtronic, INC. | $43.57 | 2024-2025 | Illumisite |
| Allergan, INC. | $41.49 | 2020 | |
| Mallinckrodt Enterprises LLC | $33.51 | 2019 | |
| Novo Nordisk INC | $32.07 | 2019 | |
| Viatris Specialty LLC | $31.22 | 2025 | Yupelri |
| Circassia INC. | $30.73 | 2019-2020 | |
| Abbott Laboratories | $24.87 | 2022 | |
| Siemens Medical Solutions USA, INC. | $22.99 | 2025 | Cios Spin |
| Azurity Pharmaceuticals, INC. | $19.63 | 2025 | Alvesco |
| Jazz Pharmaceuticals INC. | $17.71 | 2019 | |
| Tactile Systems Technology INC | $16.14 | 2024 | Flexitouch Plus, Entre Plus |
| Bayer Healthcare Pharmaceuticals INC. | $14.54 | 2025 | |
| Insulet Corporation | $14.27 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Iram Nawaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.